KAN-101 Phase 1 Clinical Trial Recruiting Now
The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingWe are well on the way to assembling a grassroots advocacy team that can help make celiac disease a national priority in communities across the country
Continue ReadingMore and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible.
Continue ReadingImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…
Continue ReadingCour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…
Continue Reading